Background: ITD-FLT3 mutations induce the refractory phenotype in patients with AML and enhance cell migration toward Cxcl12.
Internal tandem duplication mutations in the FLT3 gene (ITD-FLT3), which are observed in human acute myeloid leukemia (AML) 3 stem cells, are found in 20 -30% of patients with AML (1) (2) (3) (4) . Although ITD-FLT3 has been associated with extremely poor patient prognoses, FLT3 inhibitors fail to display significant efficacy as an anti-AML therapy (1) (2) (3) . This lack of significant efficacy of FLT3 inhibitors (1) (2) (3) suggests that targeting cells using a cell autonomous mechanism alone may not be sufficient for the treatment of ITD-FLT3 ϩ AML and that the development of additional therapeutic strategies is necessary to overcome the refractory phenotype induced by ITD-FLT3. Human AML stem cells residing in the endosteal niche of the bone marrow are relatively chemoresistant (5) . This resistance results from survival cues in the form of various cytokines and adhesion molecules produced by niche cells, which increase the resistance of these cells to cytoreductive therapies (6) . Therefore, antagonizing the interaction between leukemia cells and their niche may provide additional therapeutic bene-fits to patients with AML that is refractory to FLT3 inhibitors. Stromal cell-derived factor-1 (Cxcl12), a chemokine expressed by bone marrow osteoblasts, is responsible for retaining hematopoietic stem cells in the marrow niche (6) . Most leukemia cells express Cxcr4, a receptor for Cxcl12, and migrate in response to Cxcl12 (7) (8) (9) . Cxcr4 expression is associated with poor prognoses in patients with AML, particularly patients who are ITD-FLT3 ϩ (10, 11) . Recent studies have suggested that releasing leukemia cells from the bone marrow niche by blocking the interaction between Cxcl12 and Cxcr4 effectively increases their sensitivity to cytoreductive treatment (12, 13) . These findings suggest that the interaction between Cxcl12 and Cxcr4 facilitates the retention and homing of leukemia cells in the bone marrow niche and is associated with disease progression.
We previously reported that ITD-FLT3 mutations enhance the migration of mouse Ba/F3 and 32D cells toward Cxcl12 (14) , suggesting that ITD-FLT3 may enhance the retention and/or adherence of leukemia cells to the bone marrow microenvironment where Cxcl12 is expressed. The Cxcr4 antagonist AMD3100 selectively reduces the proliferation of ITD-FLT3 ϩ AML leukemic blasts (15) , and Cxcr4 inhibition by AMD3465 increases the sensitivity of FLT3-mutated leukemic cells to the apoptogenic effects of an FLT3 inhibitor (16) . These data suggest that ITD-FLT3-mediated retention resulting from enhanced chemotaxis toward Cxcl12 may represent one mechanism that underlies the resistance of ITD-FLT3
ϩ AML cells to chemotherapy. However, the molecular mechanism responsible for the aberrant response of ITD-FLT3 ϩ cells to Cxcl12 has not been investigated. A recent report demonstrated that Rhoassociated kinase (Rock) regulates the proliferation of ITD-FLT3 ϩ hematopoietic cells (17) . Cxcl12 regulates Rock activity, but its effects on Rock activity can be either stimulatory or inhibitory depending on the cell type and the time course examined (18 -21) . In this study, we investigated the functional role of Rock1 and the signaling network involved in the aberrant migration of ITD-Flt3 ϩ cells toward Cxcl12. Our data demonstrate that ITD-FLT3 blocks the down-regulation of Rock1, thereby augmenting the chemotaxis of these cells toward Cxcl12.
EXPERIMENTAL PROCEDURES
Antibodies and Reagents-The phycoerythrin anti-human CXCR4 (clone 12G5) and phycoerythrin anti-mouse Cxcr4 antibodies and the neutralizing antibody against mouse Cxcr4 (clone 247506) were purchased from BD Biosciences. Recombinant human FLT3 ligand (FL), recombinant murine Sdf-1␣ (Cxcl12), recombinant murine Ccl2, and the phycoerythrinconjugated anti-human/mouse Cxcr7 antibody were purchased from R&D Systems (Minneapolis, MN). AC220 and AMD3100 were purchased from Selleckchem (Houston, TX) and EMD Chemicals, Inc. (Darmstadt, Germany), respectively. CEP701 and the Cxcr7 agonist VUF11207 were purchased from Calbiochem. LY294002, Y27632, and H1152 were purchased from Wako Pure Chemicals (Osaka, Japan). The antibodies against Rock1 and Actin (I-19) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA (22) . The in vitro migration assay was performed as described previously (14) . Ba/F3 cells expressing wild-type FLT3 or ITD-FLT3 (N51 and N78) were subjected to a migration assay toward 100 ng/ml CXCL12 for 4 h. The percentage of migrated cells was calculated by dividing the number of migrated cells by the number of incubated cells and multiplying by 100. Both the cells that had migrated to the lower chamber and the input cells were collected, and the mRNA expression levels were quantified using mRNA microarrays. The microarray analyses were performed by Miltenyi Biotec (Auburn, CA). Briefly, 250 ng of each cDNA were used as a template for Cy3 and Cy5 labeling. Equal amounts of the labeled cDNAs from Ba/F3 cells expressing wild-type FLT3 or ITD-FLT3 (N51 and N78) were hybridized for 17 h at 65°C to Agilent Whole Mouse Genome Oligo Microarrays (44 K) according to the manufacturer's protocol. The differentially expressed genes were annotated and functionally classified according to the available information regarding their molecular functions and biological processes as defined by the Gene Ontology terms and the molecular pathways in the KEGG database. The significantly differentially expressed genes were annotated and assigned to functional categories using the Database for Annotation, Visualization, and Integrated Discovery, DAVID) 2008 (23) . The functional networks corresponding to the genes that were differentially expressed in response to ITD-FLT3 and/or CXCL12 were visualized using Cytoscape software (24) . The primer sequences used for RT-PCR were as follows: Rock1, 5Ј-CGACCTGTAA-CCCAAGGAGA-3Ј and 5Ј-GGCCTTTGTGATTCTGGAAA-3Ј; Rock2, 5Ј-GGCCTTGCATATTGGTATGG-3Ј and 5Ј-CAC-AGGCAATGACAACCATC-3Ј; and Hprt, 5Ј-TGGACAGGAC-TGAAAGACTTGCTCG-3Ј and 5Ј-GGCCACAATGTGATGG-CCTCCC-3Ј. The PCR cycling parameters were 95°C for 10 min, followed by 50 cycles at 95°C for 15 s and 60°C for 1 min.
Calcium Mobilization Assay-Calcium mobilization was analyzed using Fluo-4NW (Invitrogen). The cells in 1ϫ Hanks' balanced salt solution supplemented with 20 mM HEPES solution were mixed with Fluo-4NW prior to incubation in Cxcl12. The fluorescent signal (488 nm excitation) in the cells was measured immediately before and after incubation in 10 ng or 100 ng/ml Cxcl12 using a FACSCalibur flow cytometer (BD Biosciences).
Generation of Rock1 shRNA-The sequences targeting Rock1 mRNA (NM_009071) were selected using BioinformaticssiRNA Designer on the Clontech website. The shRNA oligonucleotides were cloned into the pSingle-tTS-shRNA vector containing neomycin phosphotransferase as a selectable marker (Clontech). To generate cells expressing shRNA against Rock1, we first generated Ba/F3 cells expressing wild-type FLT3 or ITD-FLT3 (N51) by transducing MSCV-Flt3-EGFP, which does not carry the neomycin phosphotransferase gene (22, 25) . Then we collected the GFP-positive cells using a FACSAria II TM cell sorter (BD Biosciences). The recombinant vectors containing control shRNA or Rock1 shRNA were transfected into cells expressing wild-type FLT3 or ITD-FLT3 (N51). These cells were cultured in RPMI 1640 medium containing 10% Tet System-approved FBS (Clontech). Stable transformants were selected using 1 mg/ml G418. To activate RNA interference against Rock1, 1 g/ml doxycycline was added to the culture medium. Finally, a single clone that exhibited Rock1 knockdown was subjected to a migration assay. The Rock1-specific shRNA sequences were 5Ј-GCTGGATAAGTCTGGACAT-3Ј and 5Ј-GAGCAAATGCCAGTGAGAAC-3Ј.
Statistical Analysis-The data are expressed as the means Ϯ S.E. of the mean, and statistical significance was evaluated using Microsoft Excel (Microsoft Corp., Seattle, WA) via the twotailed Student's t test. Fig. 1A, left panel) . The increased migration of ITD-FLT3 cells was not due to increased cell proliferation during the 24-h period, as the proportion of cells that migrated was significantly higher than that of cells that proliferated during this period (data not shown). Treatment with CEP-701, a tyrosine kinase inhibitor that inhibits FLT3 kinase activity, decreased the ITD-FLT3-induced migration of Ba/F3 cells (p Ͻ 0.05; Fig. 1A, right panel) . Similarly, AC220, a more specific and potent antagonist of ITD-FLT3 (27) , significantly inhibited the migration of ITD-FLT3 ϩ Ba/F3 cells (p Ͻ 0.05; Fig. 1A, right panel) . ITD-FLT3 mutations (N51 and N78) significantly increased the migration of Ba/F3 cells toward 100 ng/ml Cxcl12 compared with ITD-FLT3 Ϫ Ba/F3 cells during a 24-h period (Fig. 1B, top panel) . The superior migration of ITD-FLT3-expressing cells was also detected in the presence of a Cxcl12 concentration of 1, 10, 50, or 500 ng/ml (Fig. 1B, bottom panel) . The migration of ITD-FLT3 ϩ Ba/F3 cells was the highest at concentrations between 10 and 100 ng/ml. In contrast, the migration of ITD-FLT3 Ϫ Ba/F3 cells peaked at concentrations between 1 and 50 ng/ml. Conversely, the migration of ITD-FLT3
RESULTS

ITD-Flt3-induced Enhancement of Cell Migration toward
ϩ Ba/F3 cells toward Cxcl12 was inhibited by treatment with AC220 in a dose-dependent manner (Fig. 1B, center panel) . Similarly, AC220 and CEP-701 reduced the migration of human leukemia MV4-11 cells harboring endogenous ITD-FLT3 toward Cxcl12 (Fig. 1B, right  panel) . A neutralizing antibody against Cxcr4 significantly inhibited the enhanced migration of ITD-FLT3
ϩ Ba/F3 cells toward Cxcl12, and this inhibitory effect was exacerbated by combined treatment with AC220 (Fig. 1C, left panel) . Similar results were found following treatment with CEP-701 and/or the Cxcr4 antagonist AMD3100 (Fig. 1C, right panel) .
Despite the enhancement in cell migration toward Cxcl12, the Cxcr4 mRNA and Cxcr4 protein surface expression levels were consistently lower in ITD-FLT3 ϩ Ba/F3 cells than in ITD-FLT3 Ϫ cells (Fig. 1D, left panel) . Moreover, Cxcr4 expression was further down-regulated by Cxcl12 in ITD-FLT3 ϩ cells (Fig.  1D, left panel) . Comparison of the Cxcr4 expression levels in different human AML cell lines using gene expression data from the public gene expression profile database (26) demonstrated that Cxcr4 mRNA expression was significantly lower in ITD-FLT3 ϩ AML cells (n ϭ 78) than in ITD-FLT3 Ϫ AML cells (n ϭ 190, p Ͻ 0.05; Fig. 1D, right panel) . Consistent with these data, the Cxcr4 protein surface expression levels in human MV4-11 acute leukemia cells expressing ITD-FLT3 was lower than that in RS4;11 cells, which express wild-type FLT3 (p Ͻ 0.05; Fig. 1D, right panel) . The expression of Cxcr7, another receptor of Cxcl12 that mediates Cxcl12 signaling (28, 29) , was barely detectable in both ITD-FLT3 ϩ and ITD-FLT3 Ϫ Ba/F3 cells. Although CXCR7 was expressed on the surface of ITD-FLT3 ϩ MV4-11 cells, the CXCR7 agonist VUF11207, which recruits ␤-arrestin2 at a concentration of 1.6 nM (30), failed to induce the migration of these cells at 2 or 20 nM (data not shown). Because ITD-FLT3 enhances cell migration toward Cxcl12 despite a reduction in the expression level of Cxcr4, we next examined whether ITD-FLT3 mutations enhance calcium mobilization and the phosphorylation of Erk p42/p44 and Creb in response to Cxcl12 stimulation. Calcium mobilization immediately after incubation in either 10 or 100 ng/ml Cxcl12 were equivalent or significantly reduced in ITD-FLT3
ϩ Ba/F3 cells compared with ITD-FLT3 Ϫ Ba/F3 cells (Fig. 1E ). Although incubation in Cxcl12 enhances Erk p42/p44 and Creb phosphorylation in Ba/F3 cells expressing wild-type FLT3 (14) or three different types of ITD-FLT3, ITD-FLT3 mutation failed to enhance Cxcl12-induced phosphorylation (Fig. 1F ). These data suggest that the enhanced migration toward Cxcl12 mediated by ITD-FLT3 does not correlate to an increase in Cxcr4 signaling. Ϫ Ba/F3 cells to identify the pathways that are potentially involved in ITD-FLT3-induced cell migration. The expression of 1,274 mRNAs was up-regulated, whereas that of 569 mRNAs was down-regulated by more than 50% in the cells expressing N51-and N78-ITD-FLT3. Classification of the genes according to the KEGG database indicated that genes associated with leukocyte transendothelial migration, regulation of the actin cytoskeleton, and the chemokine signaling pathway were significantly regulated by ITD-FLT3 (p Ͻ 0.05; Fig. 2A ). The similar classification of a gene expression profile deposited in the public expression profile database (GSE1159: www.ncbi.nlm.nih.gov) demonstrated that genes associated with the regulation of cell migration, actin cytoskeleton organization, cell motility, and cell adhesion molecule binding were significantly enriched among the genes differen- ϩ AML (78 cases) and ITD-FLT3 Ϫ AML (190 cases). The CXCR4 levels were analyzed using three CXCR4 probes, which were deposited in a public gene expression database (GSE1159, www.ncbi.nlm.nih.gov) (26) (*, p Ͻ 0.05). The right bar graph indicates the relative surface expression of CXCR4 in MV4-11 cells that express endogenous ITD-FLT3 compared with RS4;11 cells, which do not harbor ITD-FLT3, as determined via flow cytometry (*, p Ͻ 0.05, n ϭ 3). E, calcium mobilization in the ITD-FLT3 ϩ (N51) and ITD-FLT3 Ϫ Ba/F3 cells stimulated with 10 or 100 ng/ml Cxcl12. The fold-increase in fluorescence following stimulation with Cxcl12 compared with before incubation is shown (*, p Ͻ 0.05, n ϭ 3). F, IL-3-deprived ITD-FLT3
ITD-Flt3 Modulates the Cxcl12-induced Changes in Gene Expression
Ϫ and ITD-FLT3 ϩ Ba/F3 cells (1, N51; 2, N73; and 3, N78) were incubated in 100 ng/ml Cxcl12 for 10 min. Erk p42/p44 and Creb phosphorylation was determined via Western blot analyses before and after incubation in Cxcl12. The signal of the protein was measured and analyzed using the densitometer in the Odyssey infrared imaging system (LI-COR biosciences, Lincoln, NE). The relative expression level of each phosphorylated protein compared with total protein is shown below the blots. ϩ cells but not in control cells (Fig. 2C ). These data demonstrate that ITD-FLT3 modulates genes downstream of Cxcl12 that are functionally distinct from those affected in ITD-FLT3 Ϫ cells. FLT3 Signaling Antagonizes the Cxcl12-induced Down-regulation of Rock Expression-One of the genes that was differentially regulated by Cxcl12 depending on the FLT3 status was Rock1, the expression of which was down-regulated in ITD-FLT3 Ϫ cells but not in ITD-FLT3 ϩ cells. Because Rock1 is a critical mediator of cell adhesion and migration, we investigated whether differences in Rock1 expression underlie the modulation of ITD-FLT3-mediated Cxcl12-induced cell migration. Microarray analyses indicated that Rock1 expression was down-regulated in ITD-FLT3
Ϫ cells by 23 Ϯ 9% (n ϭ 4, p Ͻ 0.05) following a 4-h migration toward 100 ng/ml Cxcl12. This reduction in Rock1 was validated via quantitative RT-PCR (55 Ϯ 9% reduction, n ϭ 5, p Ͻ 0.05) and Western blot analyses Interaction between CXCR4 Signaling and ITD-Flt3 NOVEMBER 7, 2014 • VOLUME 289 • NUMBER 45 (Fig. 3A) . Despite the Cxcl12-induced reduction in Rock1 expression, treatment with the Rock inhibitor Y27632 significantly inhibited the migration of ITD-FLT3 Ϫ Ba/F cells toward 100 ng/ml Cxcl12 in a dose-dependent manner (n ϭ 3, p Ͻ 0.05; Fig. 3B ), indicating that Rock1 is required for Cxcl12-induced cell migration. Because the paradoxical down-regulation of Rock1 by Cxcl12 does not adequately explain the requirement of Rock1 for cell migration toward Cxcl12, we examined the time course of Rock1 expression in response to Cxcl12. Incubating control cells lacking ITD-FLT3 in 1, 10, or 50 ng/ml Cxcl12 significantly up-regulated Rock1 mRNA; however, Rock1 mRNA expression returned to baseline after 4 h in the presence of 10 or 50 ng/ml Cxcl12 (Fig. 3C, left panel) . These alterations in Rock1 mRNA expression were dependent on the concentration of Cxcl12. Whereas the Rock1 mRNA levels continued to increase in the cells incubated in 1 ng/ml Cxcl12, Rock1 expression was significantly down-regulated after 4 h in the presence of 100 ng/ml Cxcl12 (Fig. 3C, right panel) . Therefore, Rock1 mRNA is up-regulated shortly after Cxcl12 stimulation, but it is subsequently down-regulated in the presence of 100 ng/ml Cxcl12.
In contrast to the effects of Cxcl12, Rock1 mRNA expression was up-regulated following a 4-h incubation of Ba/F cells expressing wild-type FLT3 in FLT3 ligand (FL) in a dose-dependent manner (n ϭ 3, p Ͻ 0.05; Fig. 3D) . Moreover, the Cxcl12-induced reduction in Rock1 mRNA expression was abrogated by treatment with 10 or 100 ng/ml FL (Fig. 3E, left panel) . In the control cells, treatment with both 100 ng/ml FL and Cxcl12 up-regulated Rock1 mRNA expression compared with treatment with Cxcl12 alone (55 Ϯ 19% increase, n ϭ 3, p Ͻ 0.01; Fig.  3E, left panel) , which coincided with an enhancement in cell migration toward Cxcl12 (Fig. 3E, right panel) . The FL-induced enhancement of migration toward Cxcl12 was inhibited by the Rock inhibitor H1152 (Fig. 3E, bottom panel) . Similar to Rock1, Rock2 mRNA expression was also up-regulated by FL in a dosedependent manner (Fig. 3F, left panel) . Whereas Cxcl12 decreased the expression of Rock2 after a 4-h incubation period, FL inhibited the Cxcl12-induced reduction in Rock2 mRNA expression (Fig. 3F, right panel) . These data indicate that FLT3 signaling antagonizes the Cxcl12-induced down-regulation of Rock1 and Rock2 mRNA expression.
Enhanced Cell Migration toward Cxcl12 by ITD-FLT3 Is Mediated by Blocking the Down-regulation of Rock1-Similar to FL treatment, ITD-FLT3 mutations increased Rock1 mRNA expression compared with the control Flt3 (2.1 Ϯ 0.5-, 2.2 Ϯ 0.2-, and 3.2 Ϯ 0.6-fold increases for N51, N73, and N78, respectively; p Ͻ 0.05; Fig. 4A, upper left panel) . The elevation in the Rock1 mRNA expression level was accompanied by the enhanced phosphorylation of Mypt1, a substrate of Rho kinase, as reported previously (Fig. 4A, lower left panel) (17) . Although there was no difference in the ROCK1 mRNA expression level between ITD-FLT3 ϩ and ITD-FLT3 Ϫ primary bone marrow samples derived from patients with M1 or M2 AML, the ROCK1 mRNA expression levels in the ITD-FLT3 ϩ patients with M3, M4, M5, or M6 (n ϭ 34) were higher than in the ITD-FLT3
Ϫ AML samples that have been deposited in the public database (GSE 1159, n ϭ 101, p Ͻ 0.05; Fig. 4A, upper right  panel) . Consistent with the elevation in Rock1 expression, treat- ment with the Rock inhibitor Y27632 dose-dependently inhibited the baseline migration of ITD-FLT3 ϩ Ba/F3 cells (n ϭ 3, p Ͻ 0.05; Fig. 4A, lower right panel) . Although Rock1 expression returned to baseline levels or below in ITD-FLT3 Ϫ Ba/F cells following incubation in 50 -100 ng/ml Cxcl12 for 4 h, it remained largely unaffected by Cxcl12 in ITD-FLT3 ϩ cells (N51) (Fig. 4, B and C) . Rock1 expression was significantly higher in all of the ITD-FLT3 ϩ cells (N51, N73, and N78) incubated in Cxcl12 than in the corresponding ITD-FLT3 Ϫ Ba/F cells (2.2 Ϯ 0.5-, 4.2 Ϯ 1.1-, and 1.4 Ϯ 0.2-fold increases in the N51, N73, and N78 cells, respectively; p Ͻ 0.02; Fig. 4D ). Similar to Rock1, the mRNA expression of Adducin2, a downstream effector of Rock1 (31), is significantly down-regulated by 100 ng/ml Cxcl12 in ITD-FLT3 Ϫ cells. In contrast, Adducin2 mRNA was up-regulated by Cxcl12 in ITD-FLT3 ϩ (N51) cells (Fig. 4E) . Similar to mRNA for Rock1, Rock1 protein was transiently up-regulated by 1, 10, or 100 ng/ml CXcl12, reaching up to a 2.1 Ϯ 0.3-fold higher level compared with the baseline (p Ͻ 0.03). However, Rock1 expression was consistently down-regulated over time in the control ITD-FLT3 Ϫ cells, and it was significantly lower at 6 h (0.67 Ϯ 0.1-fold, p Ͻ 0.01) compared with their peak level (Fig. 4F) . In contrast, the baseline Rock1 protein was 2.3 Ϯ 0.5-fold (p Ͻ 0.05) higher in ITD-FLT3
ϩ cells compared with ITD-FLT3 Ϫ cells, which was largely unaffected and remained elevated in the ITD-FLT3 ϩ cells even after stimulation with Cxcl12 (Fig. 4F) . Although Cxcl12 enhanced the phosphorylation of MYPT1, a downstream substrate of Rock1, in ITD-FLT3
Ϫ and ITD-FLT3 ϩ cells, its phosphorylation level was higher in ITD-FLT3 ϩ cells after 60 min than in ITD-FLT3 Ϫ cells (Fig. 4G ). Similar to FL stimulation, ITD-FLT3 significantly increased Rock2 mRNA expression in Ba/F cells (Fig.  4H) . Incubating ITD-FLT3 ϩ Ba/F cells in the Rock inhibitors H1152 and Y27632 significantly and dose-dependently inhib- ited their migration toward Cxcl12 (Fig. 4I, left panel) . Consistent with these results, two different shRNAs specific for Rock1 abrogated the enhanced migration of ITD-FLT3 ϩ cells toward Cxcl12 (p Ͻ 0.03; Fig. 4I, right panel) . These results indicate that Rock1 is responsible for the enhanced migration of ITD-FLT3 ϩ cells toward Cxcl12. Consistent with the activation of Rock1 via the PI3K pathway (17) and similar to the inhibitory effects of Rock1 antagonists on cell migration, the PI3K inhibitor LY294002 reduced the enhanced migration of ITD-FLT3 ϩ cells toward Cxcl12 (n ϭ 3, p Ͻ 0.05; Fig. 4J) .
Finally, the effects of ITD-FLT3 on cell migration in response to other chemokines were investigated. The protein expression level of Ccr2, a receptor of the chemokine Ccl2 (32), in ITDFlt3 ϩ Ba/F cells was equivalent to that in ITD-FLT3 Ϫ cells (Fig.  4K, top panel) . Whereas the control ITD-FLT3
Ϫ Ba/F3 cells failed to migrate toward 1, 5, 10, or 50 ng/ml Ccl2, ITD-FLT3 marginally but significantly enhanced the migration of Ba/F3 cells toward 5 ng/ml Ccl2 within 4 h. In ITD-FLT3 Ϫ cells exposed to 5 ng/ml Ccl2, the mRNA expression of Rock1 continued to increase, rather than being down-regulated to the basal level within 4 h. However, in ITD-FLT3
ϩ Ba/F3 cells, Rock1 expression was down-regulated within 30 min but returned to normal at 4 h in response to 5 ng/ml Ccl2 (Fig. 4K) . Based on the data presented above, we conclude that ITD-FLT3 enhances both basal and Cxcl12-induced cell migration by modulating the expression of Rock.
DISCUSSION
ITD-FLT3 is associated with a refractory phenotype and extremely poor prognosis in patients with AML (3, 4) . The chemoresistance of ITD-FLT3 ϩ AML cells may be a consequence of their enhanced chemotaxis toward Cxcl12, which is FIGURE 4 -continued expressed in the therapy-protective bone marrow niche. Therefore, identifying the molecular and cellular mechanisms underlying the migration of ITD-FLT3 ϩ cells toward Cxcl12 will aid in the development of novel strategies to eradicate resistant ITD-FLT3 ϩ AML cells that are protected in the bone marrow niche. Our study indicates that the superior migratory response to Cxcl12 mediated by ITD-FLT3 is not likely to be due to quantitative increases but rather to qualitative changes in Cxcr4 signaling. Among the differentially expressed genes, Rock1 expression was up-regulated shortly after stimulation with Cxcl12, but it was down-regulated thereafter in control ITD-FLT3 Ϫ cells. However, in ITD-FLT3 ϩ cells, Rock1 expression remained consistently elevated following incubation in Cxcl12 compared with ITD-FLT3 Ϫ cells, demonstrating that the down-regulation of Rock1, which is typically induced by Cxcl12, was blocked by ITD-FLT3. Antagonizing Rock1 abrogated the ITD-FLT3-or FL-mediated enhancement of cell migration toward Cxcl12, indicating that Rock1 mediates the enhancement of cell migration toward Cxcl12 via both normal and oncogenic FLT3 signaling. Taken together, ITD-FLT3 affects the cellular and molecular responses to Cxcl12 stimulation and augments cell migration toward Cxcl12 by blocking the down-regulation of Rock1 expression.
The role of ITD-FLT3 in cell migration is supported by the altered expression of genes that are involved in trans-endothelial migration, the actin cytoskeleton, and cell motility in ITD-FLT3 ϩ Ba/F3 cells and a published primary ITD-FLT3 ϩ AML profile compared with the expression of their ITD-FLT3 Ϫ counterparts ( Fig. 2A) . Among the genes that are associated with cell migration, the expression of Cxcr4 was down-regulated by ITD-FLT3 (Fig. 1D) . Whereas the down-regulation of Cxcr4 decreases Cxcl12/Cxcr4 signaling activity, ITD-FLT3 enhanced cell migration toward Cxcl12, suggesting that the enhanced migration toward Cxcl12 was unlikely caused by a quantitative increase in Cxcl12/Cxcr4 signaling. This implication is supported by the lack of enhancement in Cxcl12-induced calcium mobilization (Fig. 1E) or Cxcl12-induced phosphorylation of Erk p42/p44 and Creb by ITD-FLT3 (Fig. 1F) . The very low expression of Cxcr7 and the significant reduction in Cxcl12-induced migration in ITD-FLT3 ϩ cells in the presence of a Cxcr4 antagonist or a neutralizing antibody against Cxcr4 suggest that the ITD-FLT3-induced enhancement in cell migration toward Cxcl12 is mediated by Cxcr4 rather than Cxcr7. This finding is supported by the failure of CXCR7 ϩ , ITD-FLT3 ϩ MV4-11 AML cell migration in response to a CXCR7 agonist. Our mRNA microarray analysis demonstrated that ITD-FLT3 modulates the Cxcl12-induced changes in gene expression involving pathways that are functionally distinct from those in ITD-FLT3 Ϫ cells, suggesting that ITD-FLT3 qualitatively modulates Cxcl12/Cxcr4 signaling. These results also imply that the specific molecules that are differentially regulated by Cxcl12 in ITD-FLT3 ϩ and ITD-FLT3 Ϫ cells may be responsible for the aberrant migration of ITD-FLT3 ϩ cells toward Cxcl12.
One molecule that is differentially modulated by Cxcl12 in ITD-FLT3
Ϫ and ITD-FLT3 ϩ cells is Rock1, which regulates the actin cytoskeleton, cell motility, and ITD-FLT3 ϩ cell proliferation (17) . Rock activity is known to be regulated by Cxcl12, but this regulation can be either stimulatory or inhibitory depending on the cell type and time course examined (18 -21) . In control cells lacking ITD-FLT3, both the mRNA and protein levels of Rock1 were transiently up-regulated and then returned to baseline or below following exposure to Cxcl12 (Figs. 3C and  4F ). Transient up-regulation of Rock1 by Cxcl12 suggested that Rock1 is required for cell migration. The significant reductions in the migration of ITD-FLT3 Ϫ cells toward Cxcl12 using chemical inhibitors or shRNA directed against Rock1 (Figs. 3B and 4I) indicate that Rock1 expression and activity are required for Cxcl12-induced cell migration. Although the kinetics of Rock1 mRNA and protein expression were not entirely aligned, the down-regulation of Rock1 mRNA expression was pronounced at higher Cxcl12 concentrations in ITD-FLT3 Ϫ Ba/F3 cells, suggesting that this reduction in Rock1 mRNA expression requires sufficient activation of Cxcl12/Cxcr4 signaling. However, in contrast to Rock1 mRNA, the down-regulation of the Rock1 protein was delayed at a high Cxcl12 dose, suggesting that Cxcl12 may protect Rock1 protein from degradation. In normal hematopoietic cells, the initial exposure to Cxcl12 inhibits subsequent cell migration in response to additional Cxcl12 stimulation (33) . Therefore, the down-regulation of Rock1 expression may represent one mechanism that underlies the desensitization of these cells to subsequent Cxcl12 stimulation. These results suggest that the down-regulation of Rock1 expression may represent a safeguard or auto-inhibitory mechanism that prevents excessive migration in normal hematopoietic cells (Fig. 5, left panel) .
In contrast to Cxcl12, FL increased the Rock1 protein expression level in control cells, blocked the Cxcl12-induced downregulation of Rock1 expression, and increased cell migration (Fig. 3E) (14) . Similar to normal FLT3 signaling, Rock1 expression remained elevated following Cxcl12 stimulation in the presence of each of the three ITD-FLT3 mutations compared with in the control wild-type FLT3 (Fig. 4D) , indicating that FIGURE 5. Suggested model for the molecular mechanism underlying ITD-FLT3-induced aberrant cell migration. We propose that that functional cross-talk between ITD-FLT3 and Cxcl12/Cxcr4 signaling leads to aberrant cell migration. In the absence of ITD-FLT3, Rock1 is required for cell migration toward Cxcl12, and its expression is transiently up-regulated but is subsequently down-regulated. The down-regulation of Rock1 at later stages may involve a mechanism that prevents excessive cell migration. In contrast, ITD-FLT3 mutations increase Rock1 expression and inhibit its down-regulation as normally induced in the control cells. Therefore, ITD-FLT3 mutations enhance cell migration toward Cxcl12 by blocking the down-regulation of Rock1 expression.
ITD-FLT3 antagonizes the Cxcl12-induced down-regulation of Rock1 expression. The increased level of Rock1 expression in the ITD-FLT3 ϩ cells compared with the ITD-FLT3 Ϫ cells is consistent with the finding of elevated Mypt1 phosphorylation after a 4-h Cxcl12 stimulation period (Fig. 4G) . These results indicate that ITD-FLT3 stimulates the expression of Rock1 and antagonizes the down-regulation of Rock1 that normally occurs in control cells (Fig. 5, right panel) . Moreover, antagonizing Rock1 restored the migration of ITD-FLT3
ϩ Ba/F3 cells toward Cxcl12 (Fig. 4I) , indicating that Rock1 is also necessary for the ITD-FLT3-induced enhancement in cell migration toward Cxcl12. The significant inhibition of Cxcl12-induced migration in ITD-FLT3 ϩ cells that was caused by the PI3K inhibitor (Fig. 4J) is consistent with the concept that Rock1 is a downstream target of the PI3K pathway (17) . These data provide evidence that the Cxcl12/Cxcr4 and ITD-FLT3 signaling pathways functionally interact via Rock1 and that ITD-FLT3 enhances cell migration toward Cxcl12 by blocking the downregulation of Rock1 expression (Fig. 5, right panel) . Therefore, Rock1 contributes to the aberrant migration of ITD-FLT3 ϩ cells in addition to regulating their proliferation (17) . Adducin2, a downstream effector of Rock (31) , displayed the same expression profile as Rock1 in response to Cxcl12 in the control ITD-FLT3 Ϫ cells and in the ITD-FLT3 ϩ cells (Fig. 4E) . We also found that the mRNA expression of the microtubule-associated proteins Tau, endophilin, and doublecortin, all of which are known to be effector molecules of Rock1 (31) , are differentially regulated by Cxcl12 between ITD-FLT3 ϩ (N51) and control ITD-FLT3 Ϫ cells. Although it remains to be determined whether these downstream effectors are also functionally involved in the enhanced migratory response to Cxcl12 in ITD-FLT3 ϩ cells, these data support that Rock1 signaling is differentially modulated by Cxcl12 in the presence of ITD-FLT3 compared with wild-type FLT3. In addition to Cxcl12, cell migration toward Ccl2 was also enhanced by ITD-FLT3 (Fig. 4K) , indicating that the enhanced chemotaxis induced by ITD-FLT3 is not specific to Cxcl12. However, in contrast to Cxcl12, Rock1 expression was up-regulated by Ccl2 in control ITD-FLT3 Ϫ cells but was transiently down-regulated by Ccl2 in ITD-Flt3 ϩ cells. The down-regulation of Rock1 expression in response to Ccl2 contrasts with the results for Cxcl12 in ITD-FLT3 ϩ cells, suggesting that the involvement of Rock1 in cell migration may differ between Ccl2 and Cxcl12. These data indicate that although the ITD-FLT3-induced enhancement in cell migration toward chemokines is not specific to Cxcl12/Cxcr4, the mechanism underlying Rock1 downregulation in Cxcl12/Cxcr4 signaling is not always induced by ITD-FLT3 in other chemokine signaling pathways. Therefore, blocking the negative feedback mechanism regulating Rock1 expression does not merely represent a global effect of ITD-FLT3.
In summary, ITD-FLT3 mutations modulate Cxcl12/Cxcr4 signaling pathways via a functionally distinct mechanism from that of wild-type Flt3, and these mutations augment chemotaxis toward Cxcl12 by blocking the down-regulation of Rock1. The dual roles of Rock1 in aberrant proliferation (17) and migration toward Cxcl12 as a functional effector of ITD-FLT3 suggest that Rock1 plays a crucial role in the resistant phenotype by modulating the interaction between ITD-FLT3 ϩ AML cells and the bone marrow microenvironment, in addition to regulating AML cell proliferation (17) . In this regard, antagonizing Rock1 (34) may represent an additional approach to the treatment of patients with AML harboring ITD-Flt3.
